U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06852924) titled 'Inhaled Nitric Oxide for High Amplitude Pulmonary Edema (HAPE)' on Feb. 14.
Brief Summary: High Altitude Pulmonary Edema (HAPE) is a critical, non-cardiogenic pulmonary edema that manifests in high-altitude conditions, marked by the rapid onset of symptoms such as dyspnea, cough, frothy sputum, and cyanosis. It represents a significant cause of mortality among high-altitude illnesses due to its swift progression and elevated fatality rates if not addressed promptly. The pathophysiological mechanisms underlying HAPE include excessive hypoxic pulmonary vasoconstriction, increased permeability of the pulmonary vasculature, impaired cle...